109 completed. 109 Phase 3, 13 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 109 | Completed 109 |
| Phase 2 | 13 | Completed 13 |
Follow Conjunctivitis: new trials by email Literature Review of Conjunctivitis trials Research Report on Conjunctivitis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Demonstrate the Effect of REGN5713-5715 on Reducing Ocular Allergy Signs and Symptoms in Adult Participants With Birch Pollen Allergy REGN5713, REGN5715, Placebo - Allergic Conjunctivitis | Phase 3 | Completed | Regeneron Pharmaceuticals | 54 | 2024-11-19 | 2026-04-21 |
| A Study to Demonstrate How Well REGN1908-1909 Works in Reducing Ocular Allergy Signs and Symptoms in Adult Participants With Cat Allergy REGN1908, REGN1909, Placebo - Allergic Conjunctivitis | Phase 3 | Completed | Regeneron Pharmaceuticals | 64 | 2024-11-06 | 2026-05-08 |
| Vizol S DIGI EYE Efficacy and Safety Study in Patients With Dry Eye Vizol S DIGI EYE eye drops, 0,9% saline solution, eye drops - Dry Eye Disease (DED) | Phase 3 | Completed | Jadran Galenski laboratorij d.d. | 86 | 2024-03-20 | 2025-07-03 |
| Evaluation of the Safety and Pharmacokinetics of Brimonidine Tartrate 0.025%/Ketotifen Fumarate 0.035% Combination Ophthalmic Solution Brimonidine Tartrate 0.025%/Ketotifen Fumarate 0.035% Ophthalmic Solution (Combo), Vehicle of brimonidine tartrate 0.025%/ketotifen fumarate 0.035% ophthalmic solution - Allergic Conjunctivitis | Phase 3 | Completed | Bausch & Lomb Incorporated | 512 | 2023-04-20 | 2025-07-10 |
| Evaluation of Brimonidine Tartrate/Ketotifen Fumarate Combination for the Treatment of Allergic Conjunctivitis Brimonidine tartrate 0.025%/ketotifen fumarate 0.035%, Brimonidine Tartrate 0.025%, Ketotifen Fumarate 0.035% - Allergic Conjunctivitis | Phase 3 | Completed | Bausch & Lomb Incorporated | 188 | 2022-10-12 | 2025-02-14 |
| Vizol S Lipid Balance Efficacy and Safety Study in Patients With Dry Eye Vizol S LIPID BALANCE eye drops, ophthalmic saline eye drops - Dry Eye Disease | Phase 3 | Completed | Jadran Galenski laboratorij d.d. | 64 | 2022-06-01 | 2024-03-21 |
| Safety Study of Tivanisiran to Treat Dry Eye Tivanisiran sodium ophthalmic solution, Vehicle ophthalmic solution - Dry Eye Disease | Phase 3 | Completed | Sylentis, S.A. | 301 | 2022-03-24 | 2026-09-09 |
| The INVIGORATE 2 Trial: A Clinical Trial to Assess the Efficacy and Safety of Subjects With Seasonal Allergic Conjunctivitis Reproxalap Ophthalmic Solution (0.25%), Vehicle Ophthalmic Solution - Allergic Conjunctivitis | Phase 3 | Completed | Aldeyra Therapeutics, Inc. | 131 | 2022-01-21 | 2026-05-14 |
| Tivanisiran for Dry Eye in Subjects With Sjögren's Syndrome Tivanisiran sodium ophthalmic solution, Vehicle ophthalmic solution - Dry Eye Disease, Sjögren Syndrome | Phase 3 | Completed | Sylentis, S.A. | 203 | 2021-05-25 | 2024-02-20 |
| Study to Assess the Safety, Tolerability and Efficacy of Bilastine Ophthalmic Solution 0.6% in Children Bilastine, Placebo - Allergic Conjunctivitis | Phase 3 | Completed | Faes Farma, S.A. | 59 | 2021-03-26 | 2023-03-16 |
| Study to Assess the Efficacy of Anti-Bet v 1 Monoclonal Antibodies in Adults to Reduce Symptoms of Seasonal Allergic Rhinitis REGN5713, REGN5714, REGN5715 - Allergic Rhinitis, Conjunctivitis | Phase 3 | Completed | Regeneron Pharmaceuticals | 353 | 2021-01-14 | 2022-10-27 |
| Vehicle-Controlled Study of SkQ1 as Treatment for Dry-eye Syndrome SkQ1 Vehicle Solution, SkQ1 Ophthalmic Solution - Dry Eye Syndrome | Phase 3 | Completed | Mitotech, SA | 610 | 2019-12-20 | 2022-01-19 |
| The INVIGORATE Trial: A Clinical Trial to Assess the Efficacy and Safety of Subjects With Seasonal Allergic Conjunctivitis. Reproxalap Ophthalmic Solution (0.25%), Vehicle Ophthalmic Solution - Allergic Conjunctivitis | Phase 3 | Completed | Aldeyra Therapeutics, Inc. | 95 | 2019-12-05 | 2024-11-20 |
| Dose Ranging Study to Assess the Efficacy and Safety of Voclosporin Ophthalmic Solution in Subjects With Dry Eye Syndrome 0.05% Voclosporin Ophthalmic Solution (VOS), 0.10% VOS, 0.20% VOS - Dry Eye Syndrome, Keratoconjunctivitis Sicca | Phase 2 / Phase 3 | Completed | Aurinia Pharmaceuticals Inc. | 508 | 2019-10-14 | 2021-12-10 |
| A Study Evaluating the Safety and Efficacy of OTX-DP for the Treatment of Allergic Conjunctivitis Dexamethasone, 0.4mg, Placebo plug with no drug - Allergic Conjunctivitis | Phase 3 | Completed | Ocular Therapeutix, Inc. | 96 | 2019-08-05 | 2021-10-07 |
| Tavilermide Ophthalmic Solution for the Treatment of Dry Eye Tavilermide ophthalmic solution, Placebo - Keratoconjunctivitis Sicca, Dry Eye | Phase 3 | Completed | Mimetogen Pharmaceuticals USA, Inc. | 623 | 2019-03-28 | 2023-04-05 |
| Study of SkQ1 as Treatment for Dry-eye Syndrome Low Dose - SkQ1, High dose - SkQ1, SkQ1 (Vehicle) - Dry Eye Syndrome | Phase 3 | Completed | Mitotech, SA | 452 | 2018-12-06 | 2022-01-19 |
| Demonstration of Equivalence and Early Onset of a Novel Anti-allergic Nasal Spray Compared to Marketed Nasal Spray Rhinocort, Budesolv, Placebo - Allergic Rhinitis, Allergic Conjunctivitis | Phase 3 | Completed | Marinomed Biotech AG | 82 | 2018-11-19 | 2020-10-12 |
| Safety of Co-administration of IDA and Azithromycin for NTDs ( ComboNTDs ) Albendazole on Day 1, Ivermectin on Day 1, Diethylcarbamazine on day 1 - Trachoma, Yaws | Phase 3 | Completed | Lihir Medical Centre | 20000 | 2018-10-01 | 2019-02-28 |
| A Study Evaluating Bilastine Ophthalmic Solution 0.6% in the Conjunctival Allergen Challenge (Ora-CAC®) Model. Bilastine Ophthalmic Solution 0.6%, Ketotifen Ophthalmic Solution 0.025% (Zaditen), Vehicle of Bilastine Ophthalmic Solution - Allergic Conjunctivitis | Phase 3 | Completed | Faes Farma, S.A. | 228 | 2018-04-07 | 2023-03-16 |
Showing 20 of 109. Sign in to see all of them.
Conjunctivitis, Allergic (56) · Dry Eye Syndromes (23) · Keratoconjunctivitis Sicca (22) · Conjunctivitis, Bacterial (14) · Hypersensitivity (7) · Keratoconjunctivitis (4) · Rhinitis (4) · Rhinitis, Allergic (4) · Rhinitis, Allergic, Seasonal (4) · Eye Infections (3) · Trachoma (3) · Blepharitis (2) · Conjunctivitis, Viral (2) · Hyperemia (2)
Conjunctival Diseases (109) · Eye Diseases (109) · Immune System Diseases (64) · Hypersensitivity, Immediate (59) · Hypersensitivity (55) · Corneal Diseases (31) · Keratitis (26) · Infections (25) · Lacrimal Apparatus Diseases (24) · Keratoconjunctivitis (22) · Bacterial Infections (18) · Bacterial Infections and Mycoses (18) · Eye Infections (18) · Eye Infections, Bacterial (18)
Olopatadine Hydrochloride (10) · Ophthalmic Solutions (9) · Ketotifen (7) · Azithromycin (6) · Dexamethasone (4) · Loteprednol Etabonate (3) · Moxifloxacin (3) · Tacrolimus (3) · bepotastine besilate (3) · Albuterol (2) · Brimonidine Tartrate (2) · Cyclosporine (2) · Fluticasone (2) · Gatifloxacin (2) · Loratadine (2)
Bausch & Lomb Incorporated (13) · Alcon Research (11) · Vistakon Pharmaceuticals (9) · Allergan (7) · ALK-Abelló A/S (5) · Aciex Therapeutics, Inc. (4) · Aldeyra Therapeutics, Inc. (3) · Merck Sharp & Dohme LLC (3) · Mimetogen Pharmaceuticals USA, Inc. (3) · Regeneron Pharmaceuticals (3) · Sun Pharmaceutical Industries Limited (3) · Astellas Pharma Inc (2) · Campus Bio-Medico University (2) · Faes Farma, S.A. (2) · Jadran Galenski laboratorij d.d. (2)
United States (59) · Canada (7) · Japan (7) · Germany (6) · Spain (6) · France (5) · Italy (5) · India (4) · Israel (4) · Poland (4) · Brazil (3) · Australia (2) · Austria (2) · Belgium (2) · Czechia (2)
Brian Pall, OD, MS, FAAO (4) · Abhijit Narvekar, MS, MBBS (2) · Edward Meier, MD (2) · Gail L Torkildsen, MD (2) · Garth Cumberlidge, PhD (2) · Ingerman Avner, MD (2) · Jon Williams, PhD (2) · Lawrence T Friedhoff, MD, PhD (2) · Stacey Ackerman, MD (2) · Tim McNamara, PharmD (2)
PMID 25685162, PMID 21681652, PMID 22991696, PMID 24836393, PMID 25788949, PMID 26507708, PMID 27466061, PMID 17652708, PMID 18374301, PMID 19843481, PMID 20488431, PMID 20642205, PMID 21211642, PMID 21211643, PMID 21250860, PMID 21397770, PMID 22256909, PMID 22420526, PMID 22644963, PMID 23622121, PMID 23706715, PMID 24289915, PMID 24468255, PMID 24517417, PMID 25163405, PMID 25244402, PMID 25473263, PMID 26266427, PMID 26507709, PMID 27445067, PMID 28736342, PMID 28736344, PMID 33469259, PMID 33619183, PMID 34919861, PMID 36729473, PMID 36811846, PMID 37872059, PMID 38105911, PMID 38134305, PMID 38991011, PMID 39328900, PMID 41314021, PMID 41548574, PMID 42837491
2008 (2), 2016 (2), 2018 (1), R34EY017626 (1), U10EY023939 (1)